kidney diseases

Shown here are members of the team working to evaluate new drug candidates for the treatment of kidney diseases.

Kidney diseases research collaboration renewed

Vanderbilt University Medical Center and Bayer have agreed to continue a strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases.

Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

Study tracks new end-stage renal disease therapy

Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease.

Woman gives ultimate Valentine’s gift to her husband